Biopharma Daily Stock Updates - 07/15/21

$XBI $125.9 -0.01%

---

Covid Updates

$CRVS -1.7% Corvus Pharmaceuticals Discontinues Phase 3 Study of Mupadolimab (Anti-CD73) for COVID-19 Due to Vaccine Effectiveness in Reducing Hospitalizations. source

$OCGN -1.2% Ocugen, Inc. Announces Initiation of Rolling Submission to Health Canada for COVAXIN™. source

Pipeline Updates

$RVVTF 0% Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19. source

$DNLI +0.4% Denali Therapeutics to Present Interim Data from Phase 1/2 Study of ETV:IDS (DNL310) for the Potential Treatment of Hunter Syndrome at MPS 2021. source

$VIR +2.4% Vir Biotechnology Initiates Phase 2 Clinical Trial Evaluating the Combination of VIR-2218 and VIR-3434 as a Functional Cure Regimen for Chronic Hepatitis B Virus Infection. source

$RUBY +3.3% Rubius Therapeutics Announces Publication of RTX-240 Preclinical Data in Cancer Immunology, Immunotherapy. source

$BCRX +1.1% BioCryst Announces Designs for REDEEM-1 and REDEEM-2 Pivotal Trials with BCX9930 as Oral Monotherapy for Patients with PNH. source

$ARAV -1.5% Aravive Achieves Second Development Milestone from 3D Medicines. source

$SYBX +6.1% Synlogic Announces Initiation of Phase 1 Study of SYNB1934, a Next-Generation Strain for the Treatment of Phenylketonuria (PKU). source

$XOMA 0.3% XOMA Acquires Royalty and Milestone Interest in Checkmate’s Vidutolimod (CMP-001) from Kuros Biosciences. source

$TMDX -2.1% TransMedics Announces Positive FDA Advisory Committee Vote for the OCS Liver System. source

$GLPG -13.0% On 7/14 Galapagos reports positive topline results with selective TYK2 inhibitor GLPG3667 in Phase 1b psoriasis study. source

Financial Updates

$IMV -28.9% IMV Inc. Announces Pricing of Public Offering. source

$IMUX -21.5% Immunic, Inc. Announces Pricing of $45 Million Public Offering of Common Stock. source

---

Posted by FS